<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910920</url>
  </required_header>
  <id_info>
    <org_study_id>P2018/PNEUMO/PAPED</org_study_id>
    <nct_id>NCT03910920</nct_id>
  </id_info>
  <brief_title>Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center.</brief_title>
  <acronym>PAPED</acronym>
  <official_title>Cross Transmissions of Pseudomonas Aeruginosa in a Pediatric Cohort Followed-up at the Cystic Fibrosis Reference Center of the Queen Fabiola Children's University Hospital.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de Référence S.aureus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Fabiola Children's University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis is the most common hereditary autosomal recessive disease in the Caucasian&#xD;
      population. The diseases is caused by a mutation of the gene coding for the CFTR protein&#xD;
      (Cystic fibrosis transmembrane conductance regulator), an ion channel present at the apical&#xD;
      pole of the epithelial cells. The channel dysfunction induces a deficit in hydration and a&#xD;
      hyperviscosity of different exocrine secretions.&#xD;
&#xD;
      Clinically, Cystic fibrosis is a multi-systemic disease. Pulmonary and pancreatic involvement&#xD;
      are classically in the foreground. Degradation of respiratory function, associated with acute&#xD;
      and chronic infections, represents the major cause of morbidity and mortality.&#xD;
&#xD;
      Pseudomonas aeruginosa is a ubiquitous gram-negative bacillus found primarily in stagnant&#xD;
      water. Pseudomonas aeruginosa is capable of colonizing the digestive, pulmonary and urinary&#xD;
      mucosa and the skin. This bacterium is incriminated in many opportunistic infections&#xD;
      including respiratory infections in patients with cystic fibrosis. Pseudomonas aeruginosa&#xD;
      infection is the most common parenchymal lung infection in the Cystic fibrosis community.&#xD;
&#xD;
      Pseudomonas aeruginosa chronic carriage represents a factor of poor prognosis associated with&#xD;
      an increase in morbidity and mortality. Complications related to chronic carriage of&#xD;
      Pseudomonas aeruginosa justify the implementation of strategies of eviction, screening and&#xD;
      eradication of acute Pseudomonas aeruginosa infection.&#xD;
&#xD;
      In addition to Pseudomonas aeruginosa contamination of patients via the environment, hand and&#xD;
      airborne infections between patients with Cystic fibrosis have been reported. Measures to&#xD;
      eliminate cross-transmissions have therefore been implemented in a majority of hospitals.&#xD;
&#xD;
      The aim of the study is firstly to identify the number of Pseudomonas aeruginosa&#xD;
      cross-transmissions between patients with Cystic fibrosis followed-up in Cystic fibrosis&#xD;
      center of HUDERF. Investigator will use the Pulsed-Field Gel Electrophoresis to assess the&#xD;
      possibility of cross-infection.&#xD;
&#xD;
      Depending on the results, Investigator will implement new strategies to avoid future&#xD;
      cross-contamination in our different places of care (consultation, hospitalization,&#xD;
      physiotherapy…).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Pseudomonas cross infections between cystic fiborsis patients</measure>
    <time_frame>through study completion</time_frame>
    <description>Highlighting common strains (similar typing) of Pseudomonas aeruginosa in respiratory secretion using the PFGE (Pulsed-field Gel Electrophoresis)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Cross Infection</condition>
  <arm_group>
    <arm_group_label>Cystic fibrosis patients with PA</arm_group_label>
    <description>All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Respiratory secretions&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis patients followed-up in cystic fibrosis center in Brussels.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cystic fibrosis patients aged 0-20y followed in Cystic fibrosis at HUDERF&#xD;
&#xD;
          -  For each participant, both parents or legally acceptable representative(s) must sign&#xD;
             an informed consent form (ICF) indicating that they understand the purpose of, and&#xD;
             procedures required for, the study and is willing to allow the child to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Assent is also required of children capable of understanding the study (typically&#xD;
             participants 7 years of age and older).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Beghin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUDERF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

